M6A Methylation in Glioblastoma: From Molecular Mechanisms to Clinical Applications

Glioblastoma is the most common primary intracranial malignant tumor, characterized by treatment challenges and a poor prognosis.Despite standard treatment, including surgical resection combined with radiotherapy, outcomes remain unsatisfactory, with a median progression-free survival of 7 months and an overall survival of only 15 months.In recent years, RNA methylation has garnered significant attention, with N6-methyladenosine emerging as one of the most abundant epitranscriptional modifications in eukaryotic mRNAs.Regulated by methyltransferases, demethylases, and methylation reader proteins, it influences mRNA metabolism and plays a critical role in various physiological and pathological processes.It is widely believed to play a pivotal role in tumorigenesis and development by regulating various physiological and pathological processes.This paper reviews recent studies on the relationship between m6A methylation and glioblastoma, highlighting advances in its role in diagnosis, treatment, drug resistance, and prognosis.These findings aim to provide new insights for further research on m6A methylation and glioblastoma.